Selected References:
- Anderson PO. 2021. Monoclonal antibodies during breastfeeding. Breastfeed Med; 16(8):591-593.
- Jang W, et al. 2025. Use of biologics to treat asthma during pregnancy and adverse events in pregnant women and newborns: A global pharmacovigilance analysis. Int Arch Allergy Immunol; 186(9):875-888.
- Kasuya A, et al. 2019. Successful control of severe eosinophilic granulomatosis with polyangiitis in pregnancy and perinatal period: A use of mepolizumab. The Journal of Dermatology; 46(9):e309-e311.
- Marques Simões J, et al. 2026. Safety and Efficacy of Mepolizumab during Pregnancy and Postpartum. Acta Med Port; 39(3):239-240.
- Nucala® Prescribing Information. Revised 1/2022. Available online at: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF.
- Ramos CL, Namazy J. 2023. Monoclonal antibodies (biologics) for allergic rhinitis, asthma, and atopic dermatitis during pregnancy and lactation. Immunol Allergy Clin North Am; 43(1):187-197.
- Shakuntulla F, Chiarella SE. 2022. Safety of biologics for atopic diseases during pregnancy. J Allergy Clin Immunol Pract; 10(12):3149-3155.
- Sitek AN, et al. 2023. Risks and safety of biologics: A practical guide for allergists. World Allergy Organ J; 16(1):100737.
- Smith DA, et al. 2011. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet; 50(4):215-227.
- Vittorakis SK, et al. 2022. Successful and safe treatment of severe steroid depended eosinophilic asthma with mepolizumab in a woman during pregnancy. Respir Med Case Rep; 28;41:101785.
